The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Open accessAbstract
Recent experiments have demonstrated that the Polycomb group (PcG) gene EZH2 is highly expressed in metastatic prostate cancer and in lymphomas. EZH2 is a component of the PRC2 histone methyltransferase complex, which also contains EED and SUZ12 and is required for the silencing of HOX gene expression during embryonic development. Here we demonstrate that both EZH2 and EED are essential for the proliferation of both transformed and non-transformed human cells. In addition, the pRB-E2F pathway tightly regulates their expression and, consistent with this, we find that EZH2 is highly expressed in a large set of human tumors. These results raise the question whether EZH2 is a marker of proliferation or if it is actually contributing to tumor formation. Significantly, we propose that EZH2 is a bona fide oncogene, since we find that ectopic expression of EZH2 is capable of providing a proliferative advantage to primary cells and, in addition, its gene locus is specifically amplified in several primary tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
Jacobs, J. J. L., Kieboom, K., Marino, S., DePinho, R. A., & van Lohuizen, M. (1999) · Nature · doi:10.1038/16476 · Cited by 1,580
Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex
Müller, J., Hart, C. M., Francis, N. J., Vargas, M. L., Sengupta, A. K., Wild, B., Miller, E., O’Connor, M. B., Kingston, R. E., & Simon, J. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00976-5 · Cited by 1,553
Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., & Pirrotta, V. (2002) · Cell · doi:10.1016/s0092-8674(02)00975-3 · Cited by 1,536
Pollack, J. R., Sørlie, T., Perou, C. M., Rees, C. A., Jeffrey, S. S., Lønning, P. E., Tibshirani, R. J., Botstein, D., Børresen‐Dale, A., & Brown, P. O. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162471999 · Cited by 1,167
Cited by
Sorted by citations
Items 401–500 of 999
Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases
Mimori, K., Ogawa, K., Okamoto, M., Sudo, T., Inoue, H., & Mori, M. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2004.11.001 · Cited by 73
Wagener, N., Holland, D., Bulkescher, J., Crnković‐Mertens, I., Hoppe‐Seyler, K., Zentgraf, H., Pritsch, M., Buse, S., Pfitzenmaier, J., Haferkamp, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23683 · Cited by 74
Chen, Y.-T., Zhu, F., Lin, W.-R., Ying, R., Yang, Y.-P., & Zeng, L. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2990-1 · Cited by 72
Rajabi, H. N., Hiraki, M., & Kufe, D. W. (2018) · Oncogene · doi:10.1038/s41388-017-0096-9 · Cited by 71
Hypoxia-induced Expression of Carbonic Anhydrase 9 Is Dependent on the Unfolded Protein Response
van den Beucken, T., Koritzinsky, M., Niessen, H. E. C., Dubois, L. J., Savelkouls, K. G. M., Mujčić, H., Jutten, B., Kopáček, J., Pastoreková, S., van der Kogel, A. J., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.006510 · Cited by 71
Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A
Tonini, T., Bagella, L., D’Andrilli, G., Claudio, P. P., & Giordano, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207608 · Cited by 72
Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS
Ciarapica, R., Carcarino, E., Adesso, L., Salvo, M. D., Bracaglia, G., Leoncini, P. P., Dall’Agnese, A., Verginelli, F., Milano, G. M., Boldrini, R., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-139 · Cited by 72
Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2
Lau-Corona, D., Bae, W. K., Hennighausen, L. G., & Waxman, D. J. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008796 · Cited by 63
Tateishi, K., Ohta, M., Kanai, F., Guleng, B., Tanaka, Y., Asaoka, Y., Tada, M., Seto, M., Jazag, A., Lianjie, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0449 · Cited by 67
Ciarapica, R., Salvo, M. D., Carcarino, E., Bracaglia, G., Adesso, L., Leoncini, P. P., Dall’Agnese, A., Walters, Z. S., Verginelli, F., Sio, L. D., et al. (2013) · Oncogene · doi:10.1038/onc.2013.471 · Cited by 70
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
Sun, F., Chan, E., Wu, Z., Yang, X., Márquez, V. E., & Yu, Q. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0479 · Cited by 69
Altobelli, G., Bogdarina, I. G., Stupka, E., Clark, A., & Langley‐Evans, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082989 · Cited by 71
EZH2 in Bladder Cancer, a Promising Therapeutic Target
Martínez‐Fernández, M., Rubio, C., Segovia, C., López-Calderón, F., Dueñas, M., & Paramio, J. M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126000 · Cited by 68
Zhou, X., Jiao, D., Dou, M., Zhang, W., Lv, L., Chen, J., Li, L., Wang, L., & Han, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15683 · Cited by 71
The Polycomb Repressive Complex 2 Is a Potential Target of SUMO Modifications
Riising, E. M., Boggio, R., Chiocca, S., Helin, K., & Pasini, D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002704 · Cited by 68
Self-citationLysine methylation of promoter-bound transcription factors and relevance to cancer
Stark, G. R., Wang, Y., & Lu, T. (2010) · Cell Research · doi:10.1038/cr.2010.174 · Cited by 69
Karanikolas, B. D. W., Figueiredo, M. L., & Wu, L. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0121 · Cited by 68
van Galen, J. C., Dukers, D. F., Giroth, C., Sewalt, R. G. A. B., Otte, A. P., Meijer, C. J. L. M., & Raaphorst, F. M. (2004) · European Journal of Immunology · doi:10.1002/eji.200424985 · Cited by 66
Gao, S.-B., Zheng, Q., Xu, B., Pan, C.-B., Li, K., Zhao, Y., Zheng, Q., Lin, X., Xue, L., & Jin, G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0034 · Cited by 67
Age-related changes in mesenchymal stem cells identified using a multi-omics approach
Peffers, M. J., Collins, J., Fang, Y., Goljanek‐Whysall, K., Rushton, Loughlin, J. A., Proctor, C. J., & Clegg, P. (2016) · European Cells and Materials · doi:10.22203/ecm.v031a10 · Cited by 67
Nichol, J. N., Dupéré-Richer, D., Ezponda, T., Licht, J. D., & Miller, W. H. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.001 · Cited by 75
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia
Neff, T., & Armstrong, S. A. (2013) · Blood · doi:10.1182/blood-2013-02-474833 · Cited by 68
Rehman, H., Chandrashekar, D. S., Balabhadrapatruni, C., Nepal, S., Balasubramanya, S. A. H., Shelton, A., Skinner, K., Ma, A., Rao, T., Agarwal, S., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155899 · Cited by 67
Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment
Jackson, L. M., & Moldovan, G. (2022) · NAR Cancer · doi:10.1093/narcan/zcac042 · Cited by 69
Guo, J., Cai, J., Yu, L., Tang, H., Chen, C., & Wang, Z. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01836.x · Cited by 68
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma
Toll, A. D., Dasgupta, A., Potoczek, M., Yeo, C. J., Kleer, C. G., Brody, J. R., & Witkiewicz, A. K. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.03.004 · Cited by 67
Nakagawa, S., Okabe, H., Sakamoto, Y., Hayashi, H., Hashimoto, D., Yokoyama, N., Sakamoto, K., Kuroki, H., Mima, K., Nitta, H., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3135-y · Cited by 67
Balasubramanian, S., Chew, Y. C., & Eckert, R. L. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072363 · Cited by 66
Song, X., Gao, T., Wang, N., Feng, Q., You, X., Ye, T., Lei, Q., Zhu, Y., Xiong, M., Xia, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep20864 · Cited by 65
Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy
Duff, M. L., Gouju, J., Jonchère, B., Guillon, J., Toutain, B., Boissard, A., Henry, C., Guette, C., Lelièvre, E., & Coqueret, O. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0209-y · Cited by 69
Polycomb proteins in hematologic malignancies
Martin-Perez, D., Piris, M. A., & Sanchez-Beato, M. (2010) · Blood · doi:10.1182/blood-2010-05-267096 · Cited by 65
The role of EZH1 and EZH2 in development and cancer
Lee, S. H., Li, Y., Kim, H., Eum, S., Park, K., & Lee, C. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.12.174 · Cited by 73
Bonavida, B., & Kaufhold, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.011 · Cited by 66
Yu, Y., Qi, J., Xiong, J., Jiang, L., Cui, D., He, J., Chen, P., Li, L., Wu, C., Ma, T., et al. (2019) · Theranostics · doi:10.7150/thno.29520 · Cited by 66
INTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION
Tomlins, S. A., Rubin, M. A., & Chinnaiyan, A. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100047 · Cited by 66
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Porazzi, P., Nason, S., Yang, Z., Carturan, A., Ghilardi, G., Guruprasad, P., Patel, R. P., Tan, M. T., Padmanabhan, A. A., Lemoine, J., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.013 · Cited by 68
Arribas, A. J., Rinaldi, A., Mensah, A. A., Kwee, I., Cascione, L., Robles, E. F., Martinez-Climent, J. A., Oscier, D. G., Arcaini, L., Baldini, L., et al. (2015) · Blood · doi:10.1182/blood-2014-08-596247 · Cited by 67
Phosphorylation of EZH2 by CDK1 and CDK2
Zeng, X., Chen, S., & Huang, H. (2011) · Cell Cycle · doi:10.4161/cc.10.4.14722 · Cited by 66
Targeting EZH2 for Cancer Therapy: Progress and Perspective
Li, C. H., & Chen, Y. (2015) · Current Protein and Peptide Science · doi:10.2174/1389203716666150409100233 · Cited by 63
Yang, X., Li, F., Konze, K. D., Meslamani, J. E., Ma, A., Brown, P. J., Zhou, M., Arrowsmith, C. H., Kanıskan, H. Ü., Vedadi, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00855 · Cited by 65
The Multiple Facets of PRC2 Alterations in Cancers
Wassef, M. A., & Margueron, R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.012 · Cited by 72
Wassef, M. A., Luscan, A., Aflaki, S., Zielinski, D., Jansen, P. W. T. C., Baymaz, H. I., Battistella, A., Kersouani, C., Servant, N., Wallace, M. R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814634116 · Cited by 63
Alford, S. H., Toy, K. A., Merajver, S. D., & Kleer, C. G. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1591-2 · Cited by 66
RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo
Chen, Y., Xie, D., Li, W. Y., Cheung, C. M., Yao, H., Chan, C. Y., Chan, C., Xu, F.-P., Liu, Y. H., Sung, J. J. �., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.05.003 · Cited by 66
Polycomb group-dependent Cyclin A repression in DrosophilaPreprint
Martinez, A., Colomb, S., Déjardin, J., Bantignies, F., & Cavalli, G. (2006) · Genes & Development · doi:10.1101/gad.357106 · Cited by 66
Chemical Probes of Histone Lysine Methyltransferases
Kanıskan, H. Ü., & Jin, J. J. (2014) · ACS Chemical Biology · doi:10.1021/cb500785t · Cited by 63
Wyngaarden, L. A., Delgado-Olguı́n, P., Su, I.-H., Bruneau, B. G., & Hopyan, S. (2011) · Development · doi:10.1242/dev.063180 · Cited by 62
Ma, L., Lin, K., Chang, G., Chen, Y., Chen, Y., Guo, Q., Zhang, S., Jia, Z., Huang, T. T., Zhou, A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1304 · Cited by 61
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Κhan, P., Siddiqui, J. A., Maurya, S. K., Lakshmanan, I., Jain, M., Ganti, A. K., Salgia, R., Batra, S. K., & Nasser, M. W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.006 · Cited by 64
Enhancer of Zeste 2 as a Marker of Preneoplastic Progression in the Breast
Ding, L., & Kleer, C. G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2384 · Cited by 62
The JARID2–PRC2 duality: Figure 1.Preprint
Herz, H., & Shilatifard, A. (2010) · Genes & Development · doi:10.1101/gad.1921610 · Cited by 64
Ochiai (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.868 · Cited by 62
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma
Bachmann, I. M., Puntervoll, H. E., Otte, A. P., & Akslen, L. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.17 · Cited by 60
A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma
Anestopoulos, I., Sfakianos, A., Franco, R., Chlichlia, K., Panayiotidis, M. I., Kroll, D. J., & Pappa, A. (2016) · Molecules · doi:10.3390/molecules22010062 · Cited by 61
Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities
Lauschke, V. M., Barragán, I., & Ingelman‐Sundberg, M. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-053021 · Cited by 63
Epigenetic modifications in osteogenic differentiation and transformation
Thomas, D. M., & Kansara, M. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20850 · Cited by 61
Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 61
Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7/9
Mori, S., Iwase, K., Iwanami, N., Tanaka, Y., Kagechika, H., & Hirano, T. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.10.022 · Cited by 60
Eskander, R. N., Ji, T., Huynh, B., Wardeh, R., Randall, L. M., & Hoang, B. H. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318296a265 · Cited by 59
The role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 63
Role of HOTAIR in the diagnosis and prognosis of acute leukemia
Zhang, Y., Huang, S., Zhou, H., Chen, C., Tian, L.-H., & Shen, J. (2016) · Oncology Reports · doi:10.3892/or.2016.5147 · Cited by 61
Gnani, D., Romito, I., Artuso, S., Chierici, M., Stefanis, C. D., Panera, N., Crudele, A., Ceccarelli, S., Carcarino, E., Doria, V., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.34 · Cited by 60
Self-citationZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer
Zhang, P., Xiao, Z., Wang, S., Zhang, M., Wei, Y., Hang, Q., Kim, J., Yao, F., Rodriguez‐Aguayo, C., Ton, B. N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.078 · Cited by 62
Verification of EZH2 as a druggable target in metastatic uveal melanoma
Jin, B., Zhang, P., Zou, H., Ye, H., Wang, Y., Zhang, J., Yang, H., & Pan, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01173-x · Cited by 60
Yamaguchi, J., Sasaki, M., Sato, Y., Itatsu, K., Harada, K., Zen, Y., Ikeda, H., Nimura, Y., Nagino, M., & Nakanuma, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01387.x · Cited by 60
Гарипов, А. Р., Li, H., Bitler, B. G., Thapa, R. J., Balachandran, S., & Zhang, R. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0661 · Cited by 59
An RNA matchmaker protein regulates the activity of the long noncoding RNA HOTAIR
Meredith, E. K., Balas, M. M., Sindy, K., Haislop, K. S., & Johnson, A. M. (2016) · RNA · doi:10.1261/rna.055830.115 · Cited by 62
USP38 Couples Histone Ubiquitination and Methylation via KDM5B to Resolve Inflammation
Zhao, Z., Su, Z., Liang, P., Liu, D., Yang, S., Wu, Y., Ma, L., Feng, J., Zhang, X., Wu, C., et al. (2020) · Advanced Science · doi:10.1002/advs.202002680 · Cited by 58
Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer
Hussein, Y. R., Sood, A. K., Bandyopadhyay, S., Albashiti, B., Semaan, A. Y., Nahleh, Z. A., Roh, J., Han, H. D., Lopez‐Berestein, G., & Ali‐Fehmi, R. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.004 · Cited by 60
Chen, L., Ma, Y., Kim, E. Y., Yu, W., Schwartz, R. J., Qian, L. M., & Wang, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031005 · Cited by 58
Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder
Wang, H., Albadine, R., Magheli, A., Guzzo, T. J., Ball, M. W., Hinz, S., Schoenberg, M., Netto, G. J., & Gonzalgo, M. L. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.09.005 · Cited by 58
EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression
Drelon, C., Berthon, A. S., Mathieu, M., Ragazzon, B., Kuick, R. D., Tabbal, H., Septier, A., Rodriguez, S., Batisse‐Lignier, M., Sahut‐Barnola, I., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw136 · Cited by 59
Role of the EZH2 histone methyltransferase as a therapeutic target in cancer
Italiano, A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.05.003 · Cited by 60
Ye, L., Li, F., Song, Y., Yu, D., Xiong, Z., Li, Y., Shi, T., Yuan, Z., Lin, C., Wu, X., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31766 · Cited by 57
Copper in the tumor microenvironment and tumor metastasis
Kamiya, T. (2022) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.22-9 · Cited by 60
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Kazansky, Y., Cameron, D., Mueller, H. S., Demarest, P., Zaffaroni, N., Arrighetti, N., Zuco, V., Kuwahara, Y., Somwar, R., Ladanyi, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0110 · Cited by 59
Pang, J. C., Toy, K. A., Griffith, K. A., Awuah, B., Quayson, S. E., Newman, L. A., & Kleer, C. G. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2055-z · Cited by 57
Yu, H., Simons, D. L., Segall, I., Cárcamo‐Cavazos, V., Schwartz, E., Yan, N., Zuckerman, N. S., Dirbas, F. M., Johnson, D. L., Holmes, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051239 · Cited by 59
Li, Z., Xu, L., Tang, N., Xu, Y., Ye, X., Shen, S., Niu, X., Lü, S., & Chen, Z. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.05.057 · Cited by 58
Kuwabara, A., & Gruissem, W. (2014) · Journal of Experimental Botany · doi:10.1093/jxb/eru069 · Cited by 60
SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer
Lu, W., Liu, S., Li, B., Xie, Y., Izban, M. G., Ballard, B. R., Sathyanarayana, S. A., Adunyah, S. E., Matusik, R. J., & Chen, Z. (2016) · Oncogene · doi:10.1038/onc.2016.300 · Cited by 59
Naturally occurring anti-cancer agents targeting EZH2
Shahabipour, F., Caraglia, M., Majeed, M. A., Derosa, G., Maffioli, P., & Sahebkar, A. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.020 · Cited by 61
Shan, J., Al-Muftah, M., Alkowari, M. K., Abuaqel, S. W. J., Al‐Rumaihi, K., Al‐Bozom, I., Li, P., & Chouchane, L. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0218-y · Cited by 57
Sulfide regulation and catabolism in health and disease
Hou, Y., Lv, B., Du, J., Ye, M., Jin, H., Yi, Y., & Huang, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02231-w · Cited by 64
Zhou, J., Roh, J., Bandyopadhyay, S., Chen, Z., Munkarah, A. R., Hussein, Y. R., Alosh, B., Jazaerly, T., Hayek, K., Semaan, A. Y., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.07.128 · Cited by 56
Molecular Epigenetics and Genetics in Neuro-Oncology
Nagarajan, R. P., & Costello, J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.002 · Cited by 57
Boulay, G., Dubuissez, M., Rechem, C. V., Forget, A., Helin, K., Ayrault, O., & Leprince, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.320234 · Cited by 56
Self-citationSarah Derks, A., Bosch, L. J. W., Niessen, H. E. C., Moerkerk, P. T. M., van den Bosch, S. M., Carvalho, B. G., Mongera, S., Voncken, J. W., Meijer, G. A., A, A. P. D. B., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp073 · Cited by 56
Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
Eriksson, A., Lennartsson, A., & Lehmann, S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.009 · Cited by 62
Shen, J. K., Cote, G. M., Gao, Y., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2016) · Scientific Reports · doi:10.1038/srep25239 · Cited by 59
Chapter 4 Histone Demethylases and Cancer
Kampranis, S. C., & Tsichlis, P. N. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)02004-1 · Cited by 56
The Role of Histone Modifications and Variants in Regulating Gene Expression in Breast Cancer
Dalvai, M., & Bystricky, K. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9167-z · Cited by 58
PRC2 during vertebrate organogenesis: A complex in transition
Aldiri, I., & Vetter, M. L. (2012) · Developmental Biology · doi:10.1016/j.ydbio.2012.04.030 · Cited by 59
Yang, L., Ge, D., Chen, X., Qiu, J., Yin, Z., Zheng, S., & Jiang, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.198 · Cited by 55
The role of the polycomb complex in silencing α-globin gene expression in nonerythroid cells
Garrick, D., Gobbi, M. D., Samara, V., Rugless, M. J., Holland, M. L., Ayyub, H., Lower, K. M., Sloane‐Stanley, J., Gray, N., Koch, C., et al. (2008) · Blood · doi:10.1182/blood-2008-06-161901 · Cited by 54
Choi, J. H., SONG, Y. S., Yoon, J. S., Song, K. W., & Lee, Y. Y. (2010) · Apmis · doi:10.1111/j.1600-0463.2009.02579.x · Cited by 52
Role of EZH2 in the Growth of Prostate Cancer Stem Cells Isolated from LNCaP Cells
Li, K., Liu, C., Zhou, B., Bi, L., Huang, H., Lin, T., & Xu, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611981 · Cited by 53
Stem Cell Origin of Death-from-Cancer Phenotypes of Human Prostate and Breast Cancers
Glinsky, G. V. (2007) · Stem Cell Reviews and Reports · doi:10.1007/s12015-007-0011-9 · Cited by 53
Hahn, M. A., Li, A. X., Wu, X., Yang, R. H., Drew, D. A., Rosenberg, D. W., & Pfeifer, G. P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3147 · Cited by 51
Hwang, C., Giri, V. N., Wilkinson, J. C., Wright, C. W., Wilkinson, A. S., Cooney, K. A., & Duckett, C. S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9542-7 · Cited by 51
Metadata
- Authors
- Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K.
- Affiliations
- European Institute of Oncology (IT)
- IFOM (IT)
- Corresponding author
- Helin, Kristian
- Venue
- The EMBO Journal
- Published
- 2003-10-15
- Volume
- 22
- Issue
- 20
- Pages
- 5323-5335
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC213796
- OpenAlex
- W2171439874
- Cited by
- 1,196
- References
- 43
- Citations by year
- 2026: 16 · 2025: 33 · 2024: 39 · 2023: 52 · 2022: 35 · 2021: 64 · 2020: 66 · 2019: 56 · 2018: 53 · 2017: 65 · 2016: 74 · 2015: 63 · 2014: 65 · 2013: 61 · 2012: 58
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-02-12)
- Open access
- green
- europepmc.org
- Locations
- The EMBO Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- European Commission
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione Italiana per la Ricerca sul Cancro
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- EZH2, Polycomb group genes, polycomb repressive complex 2, EED, oncogenes, cell proliferation, gene amplification, prostate cancer, lymphoma, histone methyltransferase, tumor formation
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Animals, Base Sequence, Cell Division, Cell Line, DNA-Binding Proteins, Gene Amplification, Genetic Markers, Humans, Kinetics, Lymphoma, Male, Oncogenes, Promoter Regions, Genetic, Prostatic Neoplasms, Proteins, Recombinant Proteins, Transcription Factors, Transfection, Transcriptional Activation, Retinoblastoma Protein, DNA Primers, Cell Cycle Proteins, E2F Transcription Factors, Rats, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
